Hyaluronic acid-coated and Olaparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negative breast cancer. (2nd January 2022)

• Record Type: Journal Article
• Authors: Hu, Huiping; Zhang, Yu; Ji, Wenting; Mei, Hao; Wu, Tingting; He, Zihao; Wang, Kaiping; Shi, Chen
• Is Part Of: Journal of microencapsulation. Volume 39:Number 1(2022)
• Page Start: 25
• Page End: 36
• Publication Date: 2022-01-02
• Subjects: Targeted delivery system -- PEI-PLGA nanoparticles -- hyaluronic acid -- Olaparib -- TNBC; Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.1080/02652048.2021.2014586
• Languages: English
• ISSNs: 0265-2048

Abstract

Abstract: Aim: To prepare the hyaluronic acid-coated Olaparib-loaded PEI − PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect. Methods: The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining. Results: The prepared HA-Ola-PPNPs showed a diameter of ∼160 nm with a negatively charged surface (−16.9 ± 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 ± 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice. Conclusions: According to the results, the Ola-loaded and HA-coated PEI − PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment.